— Why it moved
Why NXTS Stock More Than Quadrupled Today — June 22, 2026
An AI drug-discovery headline met a 426,000-share float: $5 to $23.80 by mid-morning, then a $2.9M offering after the bell sent it back near $7.
## What moved it An AI drug-discovery announcement. Nexentis said its subsidiary MitoCareX Bio will work with AI firm Boltz to speed up small-molecule discovery against SLC proteins, targeting cancer and metabolic disease. A real press release, on a very small company.
## The mechanics The float is about 426K shares on a $3.7M cap. Roughly 60M shares traded, so the float turned over well over a hundred times. Any headline moves a structure like that, and this one had "AI" and "drug discovery" in the same sentence.
## Numbers - Cap: ~$3.7M / float: 0.43M - Day volume: ~60M (~140x the float) - Prev close: $5.08 → alert at $9.60 was already +89% - 52w range: $3.38–$8.33 (it cleared the old high premarket)
## Where it ended up Stock Pulse flagged it premarket at 8:47 AM, $9.60. It ran to $23.80 by 10:17 AM, +148% from the alert, then bled to a $12.88 close, still +34% above the alert. After the bell the company priced a $2.9M stock-and-warrant sale at $7.06 and shares fell toward $7 after hours.
## Reality check - Everything above the offering price evaporated the same evening. $23.80 at 10:17 AM, roughly $7 by dinner. - The only cash the day actually raised was $2.9M of dilution, priced 45% below the close. - This already happened. It's a breakdown of why it ran, not a reason to buy it.